Patient Education
2025 Year of the Patients
At Digestive Cancers Europe (DiCE), we have always placed patients at the heart of our mission—amplifying their voices, advocating for their nee...
ESMO Expands Globally with New Patient Advocates Working Group
ESMO is proud to announce the launch of its newly globalised Patient Advocates Working Group (PAWG), now led by Zorana Maravic as Chair. This miles...
Advancing Liver Cancer Care: Highlights from the BCLC 2024 Meeting
On November 25th and 26th, DiCE virtually attended the Barcelone Clinic Liver Cancer (BCLC) annual conference, which was titled “Forging a Multid...
Empowering Cancer Patients: SmartCARE Showcase Event
The SmartCARE Showcase Event, organised by the European Cancer Organisation, brought together patient advocates, clinicians, and IT experts to intr...
Reflecting on ENTERO 2024 – A Milestone for Early-Age Onset Digestive Cancers
On November 14 and 15, Digestive Cancers Europe (DiCE) and EuropaColon Portugal proudly hosted ENTERO 2024 in the scenic city of Porto, Portugal.Read
Advancing Rare Cancer Care: DiCE at the EURACAN Board Meeting
On the 7th and the 8th of November, Laura Urena from Digestive Cancers Europe (DiCE) and a member of EURACAN Patient Advocacy Group (EPAG), partici...
Wolfram Nolte Memorial Award 2024: Celebrating Innovation in Colorectal Cancer Care
The Wolfram Nolte Memorial Award is presented annually to projects that address the unmet needs of patients and carers affected by colorectal cance...
Tevimbra (tislelizumab) Receives New European Recommendations for Oesophageal and Gastric Cancer
Tevimbra (tislelizumab) receives CHMP recommendations for treating PD-L1-positive oesophageal squamous cell carcinoma and gastric/gastroesophageal ...
New Era in Gastric Cancer Treatment: Zolbetuximab Gains EU Approval
On September 20th, 2024, the European Commission approved zolbetuximab with chemotherapy for advanced Gastric and GastroEsophageal Junction cancers...
The POLAR Promise: Groundbreaking Survival Gains for Targeted Pancreatic Cancer Patients in Phase II Trial
Phase II trial of Pembrolizumab Immunotherapy and Olaparib (POLAR) trial new data presented at the European Society for Medical Oncology (ESMO) 202...
